SGS North America Expands Biologics Testing Capabilities in USA
Introduction:
SGS North America (SGS) has expanded its capacity and capabilities to enhance biologics testing services in the USA.
Features:
The 60,000 square-foot, state-of-the-art facility in Lincolnshire, Illinois, delivers microbiology, chemistry, and biologics testing and analysis services to support both small and large molecule testing.
The facility provides advanced biopharmaceutical testing and quality control solutions across all phases of product development. These phases include early safety assessments of cell banks and product characterisation, method development, raw material testing, and final product release.
With this expansion, the centre has improved its instrumentation, specialised biologics knowledge, and capacity to characterise novel biologics and biosimilars. These enhancements enable comprehensive analytical testing from discovery through to commercial stages in a unified facility, offering streamlined and adaptable service delivery approaches.
With the addition of scientific expertise and leading instrumentation at the Lincolnshire site, the centre is bolstering its biologics testing capabilities to for large molecule drug products that are supporting rapid advancements in novel drug discovery.
This expansion introduces new instrumentation and scientific expertise to support pharmaceutical, biopharmaceutical, and medical device sectors across the United States.
Specifications:
Name SGS North America
Type Expansion
